Synergistic gene and drug tumor therapy using a chimeric peptide

Biomaterials

Volumn 34, Issue 19, 2013, Pages 4680-4689

  Han, Kai ^a   Chen, Si ^a   Chen, Wei Hai ^a   Lei, Qi ^a   Liu, Yun ^a   Zhuo, Ren Xi ^a   Zhang, Xian Zheng ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Co delivery; DOX; P53; Peptide; Synergistic therapy

Indexed keywords

CO DELIVERIES; CONFOCAL LASER SCANNING MICROSCOPY; DOX; GROWTH INHIBITION; INTRACELLULAR DELIVERY; P53; SYNERGISTIC THERAPY; WESTERN-BLOT ANALYSIS;

DISEASE CONTROL; DNA; DRUG DELIVERY; FLOW CYTOMETRY; MICELLES; PEPTIDES; TUMORS;

GENE THERAPY;

CHIMERIC PEPTIDE; DOXORUBICIN; PEPTIDE; PROTEIN P53; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DNA DRUG COMPLEX; DRUG DELIVERY SYSTEM; DRUG RELEASE; EMBRYO; ENDOSOME; FLOW CYTOMETRY; GENE; GENE TARGETING; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICELLE; PARTICLE SIZE; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNERGISTIC GENE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ZETA POTENTIAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; CELL SURVIVAL; DNA; DOXORUBICIN; DRUG CARRIERS; FLUORENES; HELA CELLS; HUMANS; MICE; MICELLES; NEOPLASMS; PEPTIDES; PLASMIDS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84875859971     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.03.010     Document Type: Article

References (24)

1. Jones B. Tumor genetics: evaluating oncogene cooperativities. Nat Rev Genet 2012, 13:598.
2. Chi D.S., Musa F., Dao F., Zivanovic O., Sonoda Y., Barakat R.R., et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012, 124:10-14.
3. Bock C., Lengauer T. Managing drug resistance in tumor: lessons from HIV therapy. Nat Rev Cancer 2012, 12:494-501.
4. Sun T.M., Du J.Z., Yao Y.D., Mao C.Q., Dou S., Wang J., et al. Simultaneous delivery of siRNA and paclitaxel via a " two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 2011, 5:1483-1494.
5. MacDiarmid J.A., Amaro-Mugridge N.B., Madrid-Weiss J., Sedliarou I., Wetzel S., Brahmbhatt H., et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 2009, 27:643-651.
6. Han L., Huang R.Q., Li J.F., Liu S.H., Huang S.X., Jiang C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials 2011, 32:1242-1252.
7. Wang H.J., Zhao P.Q., Su W.Y., Wang S., Liao Z.Y., Chang J., et al. PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials 2010, 31:8741-8748.
8. Liu S.H., Guo Y.B., Huang R.Q., Li J.F., Huang S.X., Jiang C. Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials 2012, 33:4907-4916.
9. Lu X., Wang Q.Q., Xu F.J., Tang G.P., Yang W.T. A cationic prodrug/therapeutic gene nanocomplex for the synergistic treatment of tumors. Biomaterials 2011, 32:4849-4856.
10. Meng H., Liong M., Xia T., Li Z.X., Ji Z.X., Nel A.E., et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a tumor cell line. ACS Nano 2010, 4:4539-4550.
11. Lv H.T., Zhang S.B., Wang B., Cui S.H., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006, 114:100-109.
12. Pack D.W., Hoffman A.S., Pun S., Stayton P.S. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005, 4:581-593.
13. Nakase I., Kobayashi S., Futaki S. Endosome-disruptive peptides for improving cytosolic delivery of endosome-disruptive peptide. Biopolymers 2010, 94:763-770.
14. Wang Y., Gao S.J., Ye W.H., Yoon H.S., Yang Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5:791-796.
15. Xiong X.B., Lavasanifar A. Traceable multifunctional micellar nanocarriers for tumor-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 2011, 5:5202-5213.
16. Alexis F., Lo S.L., Wang S. Covalent attachment of low molecular weight poly(ethyleneimine) improves Tat peptide mediated gene delivery. Adv Mater 2006, 18:2174-2178.
17. Hoyer J., Neundorf I. Peptide vectors for the nonviral delivery of nucleic acids. Acc Chem Res 2012, 45:1048-1056.
18. Seth P., Willingham M.C., Pastan I. Binding of adenovirus and its external proteins to Triton X-114. J Biol Chem 1985, 260:14431-14434.
19. Kakudo T., Chaki S., Futaki S., Nakase I., Akaji K., Harashima H., et al. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 2004, 43:5618-5628.
20. Kichler A., Leborgne C., Marz J., Danos O., Bechinger B. Histidine-rich amphipathic peptide antibiotics promote efficient delivery of DNA into mammalian cells. Proc Natl Acad Sci U S A 2003, 100:1564-1568.
21. Han K., Yang J., Chen S., Chen C.J., Zhuo R.X., Zhang X.Z., et al. Novel gene transfer vectors based on artificial recombinant multi-functional oligopeptides. Int J Pharm 2012, 436:555-563.
22. Zeng X., Sun Y.X., Qu W., Zhang X.Z., Zhuo R.X. Biotinylated transferrin/avidin/biotinylated disulfide containing PEI bioconjugates mediated p53 gene delivery system for tumor targeted transfection. Biomaterials 2010, 31:4771-4780.
23. Yi W.J., Yang J., Li C., Wang H.Y., Zhuo R.X., Zhang X.Z., et al. Enhanced nuclear import and transfection efficiency of TAT peptide based gene delivery systems modified by additional nuclear localization signals. Bioconjug Chem 2012, 23:125-134.
24. Lu D.X., Wen X.T., Liang J., Gu Z.W., Zhang X.D., Fan Y.U. A pH-sensitive nano drug delivery system derived from pullulan/Doxorubicin conjugate. J Biomed Mater Res B 2009, 89B:177-183.